BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 13, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2010

View Archived Issues

Swiss scientists describe novel anticancer agents

Read More

Sekmed discloses new vaccine adjuvants

Read More

Galapagos identifies novel androgen receptor ligands

Read More

SPARC staining predicts survival in rituximab-treated patients with ABC-type DLBCL

Read More

Two-year data reported on deferasirox in beta-thalassemia patients with cardiac siderosis

Read More

Quinapril and lipoic acid show benefit in metabolic syndrome

Read More

Preclinical data disclosed on discovery of novel CCK receptor antagonist JNJ-26273364

Read More

Amgen identifies novel CXCR3 antagonists for inflammatory conditions

Read More

Preclinical studies show involvement of galectin-1 in healing after acute myocardial infarction

Read More

Merck & Co. discloses new glucagon receptor antagonists

Read More

Bristol-Myers Squibb discovers new NS5B inhibitors

Read More

FDA grants fast track designation to Genta's tesetaxel for advanced gastric cancer

Read More

Lundbeck advances new agent Lu-AE-04621 to phase I for Parkinson's disease

Read More

FDA approves TachoSil surgical patch as adjunct to hemostasis in cardiovascular surgery

Read More

Allergan and Serenity Pharmaceuticals to collaborate on development Ser-120 for nocturia

Read More

Davunetide receives FDA fast track status for progressive supranuclear palsy

Read More

Bellus Health begins phase I trial of NRM-8499 for Alzheimer's disease

Read More

Living Cell Technologies' phase I/IIa Diabecell trial in type 1 diabetes meets endpoints

Read More

Recordati signs marketing agreement with Esteve for pitavastatin

Read More

Halozyme Therapeutics strengthens commercial supply agreements for rHuPH20

Read More

Multiple Myeloma Research Consortium initiates phase Ib/II Treanda trial in multiple myeloma

Read More

NeurogesX launches capsaicin patch for postherpetic neuralgia

Read More

Mologen receives funds to develop MIDGE-based DNA vaccine for hepatitis B

Read More

Phase II trial of ranibizumab in diabetic macular edema commences enrollment

Read More

MicuRx, Cumencor and Pfizer partner to develop antibiotics for multidrug-resistant tuberculosis

Read More

RXi and TransDerm form dermatology research collaboration

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • Blood sample tubes after centrifuge

    Pre-disease plasma signature may help redefine lung cancer risk

    BioWorld
    Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
  • New 5-HT2C receptor agonists reported in Hansoh patent

    BioWorld Science
    Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
  • Virtual IPO word with stock graph and arrow

    Parabilis takes top spot, pricing largest biopharma IPO at $670M

    BioWorld
    Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing